Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy

被引：0
|
作者：
Printz, Carrie
机构：
来源：
CANCER | 2020年 / 126卷 / 09期
关键词：
D O I：
10.1002/cncr.32893
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1827 / 1827
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
    Hurvitz, Sara A.
    Martin, Miguel
    Symmans, W. Fraser
    Jung, Kyung Hae
    Huang, Chiun-Sheng
    Thompson, Alastair M.
    Harbeck, Nadia
    Valero, Vicente
    Stroyakovskiy, Daniil
    Wildiers, Hans
    Campone, Mario
    Boileau, Jean-Francois
    Beckmann, Matthias W.
    Afenjar, Karen
    Fresco, Rodrigo
    Helms, Hans-Joachim
    Xu, Jin
    Lin, Yvonne G.
    Sparano, Joseph
    Slamon, Dennis
    LANCET ONCOLOGY, 2018, 19 (01): : 115 - 126
  • [32] Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models
    Veeraraghavan, J.
    Sethunath, V.
    Qin, L.
    Shea, M. J.
    Mitchell, T.
    De Angelis, C.
    Nanda, S.
    Diala, I.
    Lalani, A. S.
    Hilsenbeck, S. G.
    Rimawi, M. F.
    Osborne, C. K.
    Schiff, R.
    CANCER RESEARCH, 2019, 79 (04)
  • [33] The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models
    Veeraraghavan, Jamunarani
    Sethunath, Vidyalakshmi
    Shea, Martin J.
    Mitchell, Tamika
    Pereira, Resel
    Qin, Lanfang
    Nanda, Sarmistha
    De Angelis, Carmine
    Goutsouliak, Kristina
    Diala, Irmina
    Lalani, Alshad S.
    Mehravaran, Sepideh
    Hilsenbeck, Susan G.
    Nagi, Chandandeep
    Gutierrez, Carolina
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Assessment of clinical benefit with trastuzumab plus chemotherapy (CT) in patients with HER2-positive (HER2+) metastatic breast cancer not achieving objective responses
    Pegram, Mark
    Yeon, Christina
    Patel, Ravi
    Cartmell, Alan
    Leyland-Jones, Brian
    Klein, Pam
    Eiermann, Wolfgang
    Wolter, Janet
    Lieberman, Grazyna
    Slamon, Dennis
    ANNALS OF ONCOLOGY, 2004, 15 : 29 - 30
  • [35] Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takahashi, Katsuyuki
    Hatano, Takaharu
    Takashima, Tsutomu
    Tomita, Shuhei
    Motomura, Hisashi
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2017, 37 (10) : 5623 - 5630
  • [36] Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
    Ma, Xiangmin
    Zhang, Xiangmei
    Zhou, Xinping
    Ren, Xiaofei
    Ma, Xindi
    Zhang, Weifang
    Yang, Ruiling
    Song, Tao
    Liu, Yunjiang
    MEDICINE, 2022, 101 (40) : E30892
  • [37] Cardiac safety of neoadjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel/pertuzumab/ trastuzumab for HER2-positive breast cancer patients
    Douganiotis, George
    Grigoriadis, Savvas
    Kontovinis, Loukas
    Markopoulou, Efrosini
    Pouptsis, Athanasios
    Papazisis, Konstantinos
    JOURNAL OF BUON, 2021, 26 (03): : 714 - 719
  • [38] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [39] Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients
    不详
    ONCOLOGY-NEW YORK, 2005, 19 (07): : 851 - +
  • [40] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
12345